Tiantom Jarutat

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Marc S. Raab, Monika Engelhardt, Antje Blank et al. · The Lancet Haematology · 2020 · 79 citations

Medicine, Hematology, Oncology +14

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

Ulrik Lassen, Didier Meulendijks, L.L. Siu et al. · Clinical Cancer Research · 2014 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Systematic comparison of tissue fixation with alternative fixatives to conventional tissue fixation with buffered formalin in a xenograft-based model

Thorben Nietner, Tiantom Jarutat, Alfred Mertens · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2012 · 39 citations · Full text

Medicine, Oncology, Pathology +9

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt et al. · Blood · 2016 · 38 citations

Medicine, Hematology, Oncology +16

Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays

Maziar Assadi, Jens Lamerz, Tiantom Jarutat et al. · Molecular & Cellular Proteomics · 2013 · 29 citations · Full text

Medicine, Oncology, Pathology +17